June 11, 2019 / 5:09 AM / 2 months ago

BRIEF-Roche Holding Announces Positive Phase II Lupus Nephritis Study Results For Genentech's Gazyva (Obinutuzumab)

June 11 (Reuters) - ROCHE HOLDING AG:

* GENENTECH’S GAZYVA (OBINUTUZUMAB) DELIVERS POSITIVE TOPLINE RESULTS FOR PHASE II LUPUS NEPHRITIS STUDY

* PHASE II STUDY MET BOTH PRIMARY AND KEY SECONDARY ENDPOINTS

* NOBILITY SHOWED THAT GAZYVA HELPED MORE PATIENTS ACHIEVE A COMPLETE RENAL RESPONSE WHEN ADDED TO STANDARD OF CARE Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below